Adenocarcinoma of the Gastroesophageal Junction

About
Mappings

NCI Thesaurus: Gastroesophageal Junction Adenocarcinoma (coding:ncit:C9296)

OncoTree: Adenocarcinoma of the Gastroesophageal Junction (coding:oncotree:GEJ)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this cancer type.

Organizations
Biomarkers
Cancer types
Therapies
Organizations Biomarkers Cancer types Therapies
FDA (2) HER2-positive Adenocarcinoma of the Gastroesophageal Junction Capecitabine
EMA (1) FDA (2) HER2-positive, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Cisplatin, Fluorouracil, Pembrolizumab, Trastuzumab
FDA (2) HER2-positive, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Oxaliplatin, Pembrolizumab, Trastuzumab
FDA (2) HER2-negative Adenocarcinoma of the Gastroesophageal Junction Cisplatin, Fluorouracil, Pembrolizumab
FDA (2) HER2-negative Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Oxaliplatin, Pembrolizumab
FDA (2) PD-L1 (CPS) >= 10 Adenocarcinoma of the Gastroesophageal Junction Pembrolizumab
FDA (2) HER2-positive Adenocarcinoma of the Gastroesophageal Junction Trastuzumab
EMA (1) FDA (2) HER2-positive Adenocarcinoma of the Gastroesophageal Junction Trastuzumab deruxtecan
EMA (1) FDA (2) CLDN18.2 >= 75%, HER2-negative Adenocarcinoma of the Gastroesophageal Junction Fluorouracil, Oxaliplatin, Zolbetuximab
EMA (1) FDA (2) CLDN18.2 >= 75%, HER2-negative Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Oxaliplatin, Zolbetuximab
EMA (1) ERBB2 amplification Adenocarcinoma of the Gastroesophageal Junction Trastuzumab deruxtecan
EMA (1) HER2-positive, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Carboplatin, Fluorouracil, Pembrolizumab, Trastuzumab
EMA (1) HER2-negative, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Cisplatin, Fluorouracil, Pembrolizumab
EMA (1) HER2-negative, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Carboplatin, Fluorouracil, Pembrolizumab
EMA (1) HER2-negative, PD-L1 (CPS) >= 5 Adenocarcinoma of the Gastroesophageal Junction Fluorouracil, Nivolumab, Oxaliplatin
EMA (1) PD-L1 (TAP) >= 5% Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Oxaliplatin, Tislelizumab
EMA (1) PD-L1 (TAP) >= 5% Adenocarcinoma of the Gastroesophageal Junction Cisplatin, Fluorouracil, Tislelizumab
FDA (2) HER2-negative, PD-L1 (TAP) >= 1% Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Oxaliplatin, Tislelizumab
FDA (2) HER2-negative, PD-L1 (TAP) >= 1% Adenocarcinoma of the Gastroesophageal Junction Cisplatin, Fluorouracil, Tislelizumab
FDA (2) HER2-negative, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Oxaliplatin, Tislelizumab
FDA (2) HER2-negative, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Cisplatin, Fluorouracil, Tislelizumab
EMA (1) HER2-negative, PD-L1 (CPS) >= 5 Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Nivolumab, Oxaliplatin